Literature DB >> 18329748

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles.

Richard J Halsey1, Fiona L Tanzer, Ann Meyers, Sirika Pillay, Alisson Lynch, Enid Shephard, Anna-Lise Williamson, Edward P Rybicki.   

Abstract

HIV-1 Pr55 Gag virus-like particles (VLPs) are strong immunogens with potential as candidate HIV vaccines. VLP immunogenicity can be broadened by making chimaeric Gag molecules: however, VLPs incorporating polypeptides longer than 200 aa fused in frame with Gag have not yet been reported. We constructed a range of gag-derived genes encoding in-frame C-terminal fusions of myristoylation-competent native Pr55Gag and p6-truncated Gag (Pr50Gag) to test the effects of polypeptide length and sequence on VLP formation and morphology, in an insect cell expression system. Fused sequences included a modified reverse transcriptase-Tat-Nef fusion polypeptide (RTTN, 778 aa), and truncated versions of RTTN ranging from 113 aa to 450 aa. Baculovirus-expressed chimaeric proteins were examined by western blot and electron microscopy. All chimaeras formed VLPs which could be purified by sucrose gradient centrifugation. VLP diameter increased with protein MW, from approximately 100 nm for Pr55Gag to approximately 250 nm for GagRTTN. The presence or absence of the Gag p6 region did not obviously affect VLP formation or appearance. GagRT chimaeric particles were successfully used in mice to boost T-cell responses to Gag and RT that were elicited by a DNA vaccine encoding a GagRTTN polypeptide, indicating the potential of such chimaeras to be used as candidate HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329748     DOI: 10.1016/j.virusres.2008.01.012

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  13 in total

1.  From plant virology to vaccinology: The road less travelled.

Authors:  Edward Rybicki
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens.

Authors:  Trudy G Morrison
Journal:  Future Virol       Date:  2010-09-01       Impact factor: 1.831

3.  Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production.

Authors:  Alisson G Lynch; Fiona Tanzer; Malcolm J Fraser; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2010-03-31       Impact factor: 2.563

4.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19

5.  Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins.

Authors:  Lori W McGinnes; Trudy G Morrison
Journal:  Curr Protoc Microbiol       Date:  2013-10-02

6.  Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States.

Authors:  Sylvain Cecchini; Alejandro Negrete; Tamas Virag; Barney S Graham; Jeffrey I Cohen; Robert M Kotin
Journal:  Clin Vaccine Immunol       Date:  2009-02-25

7.  The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine.

Authors:  Fiona L Tanzer; Enid G Shephard; Kenneth E Palmer; Marieta Burger; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2011-02-07       Impact factor: 4.099

Review 8.  Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Authors:  Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

Review 9.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

10.  Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.

Authors:  Ziyaad Valley-Omar; Ann E Meyers; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2011-10-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.